310 related articles for article (PubMed ID: 32298798)
21. Screening a fragment cocktail library using ultrafiltration.
Shibata S; Zhang Z; Korotkov KV; Delarosa J; Napuli A; Kelley AM; Mueller N; Ross J; Zucker FH; Buckner FS; Merritt EA; Verlinde CL; Van Voorhis WC; Hol WG; Fan E
Anal Bioanal Chem; 2011 Sep; 401(5):1585-91. PubMed ID: 21750879
[TBL] [Abstract][Full Text] [Related]
22. Small-world phenomena in chemical library networks: application to fragment-based drug discovery.
Tanaka N; Ohno K; Niimi T; Moritomo A; Mori K; Orita M
J Chem Inf Model; 2009 Dec; 49(12):2677-86. PubMed ID: 19961207
[TBL] [Abstract][Full Text] [Related]
23. Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery.
Zimmermann MO; Lange A; Wilcken R; Cieslik MB; Exner TE; Joerger AC; Koch P; Boeckler FM
Future Med Chem; 2014 Apr; 6(6):617-39. PubMed ID: 24895892
[TBL] [Abstract][Full Text] [Related]
24. Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia.
Keserű GM; Erlanson DA; Ferenczy GG; Hann MM; Murray CW; Pickett SD
J Med Chem; 2016 Sep; 59(18):8189-206. PubMed ID: 27124799
[TBL] [Abstract][Full Text] [Related]
25. Fragment based drug design: from experimental to computational approaches.
Kumar A; Voet A; Zhang KY
Curr Med Chem; 2012; 19(30):5128-47. PubMed ID: 22934764
[TBL] [Abstract][Full Text] [Related]
26. Fragment-Based Drug Discovery in the Bromodomain and Extra-Terminal Domain Family.
Radwan M; Serya R
Arch Pharm (Weinheim); 2017 Aug; 350(8):. PubMed ID: 28714212
[TBL] [Abstract][Full Text] [Related]
27. Applications of chemogenomic library screening in drug discovery.
Jones LH; Bunnage ME
Nat Rev Drug Discov; 2017 Apr; 16(4):285-296. PubMed ID: 28104905
[TBL] [Abstract][Full Text] [Related]
28. Using fragment-based technologies to target protein-protein interactions.
Bower JF; Pannifer A
Curr Pharm Des; 2012; 18(30):4685-96. PubMed ID: 22650253
[TBL] [Abstract][Full Text] [Related]
29. Protocols for the Design of Kinase-focused Compound Libraries.
Jacoby E; Wroblowski B; Buyck C; Neefs JM; Meyer C; Cummings MD; van Vlijmen H
Mol Inform; 2018 May; 37(5):e1700119. PubMed ID: 29116686
[TBL] [Abstract][Full Text] [Related]
30. High-Throughput Kinetic Analysis for Target-Directed Covalent Ligand Discovery.
Craven GB; Affron DP; Allen CE; Matthies S; Greener JG; Morgan RML; Tate EW; Armstrong A; Mann DJ
Angew Chem Int Ed Engl; 2018 May; 57(19):5257-5261. PubMed ID: 29480525
[TBL] [Abstract][Full Text] [Related]
31. Selection Method of DNA-Encoded Chemical Library for Irreversible Covalent Binders.
Zhu Z
Methods Mol Biol; 2022; 2541():165-172. PubMed ID: 36083555
[TBL] [Abstract][Full Text] [Related]
32. Recent progress in fragment-based lead discovery.
Schulz MN; Hubbard RE
Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
[TBL] [Abstract][Full Text] [Related]
33. Fragment-Based Phenotypic Lead Discovery: Cell-Based Assay to Target Leishmaniasis.
Ayotte Y; Bilodeau F; Descoteaux A; LaPlante SR
ChemMedChem; 2018 Jul; 13(14):1377-1386. PubMed ID: 29722149
[TBL] [Abstract][Full Text] [Related]
34. SPR-based fragment screening: advantages and applications.
Neumann T; Junker HD; Schmidt K; Sekul R
Curr Top Med Chem; 2007; 7(16):1630-42. PubMed ID: 17979772
[TBL] [Abstract][Full Text] [Related]
35. How Size Matters: Diversity for Fragment Library Design.
Shi Y; von Itzstein M
Molecules; 2019 Aug; 24(15):. PubMed ID: 31387220
[TBL] [Abstract][Full Text] [Related]
36. Hit triage using efficiency indices after screening of compound libraries in drug discovery.
Reitz AB; Smith GR; Tounge BA; Reynolds CH
Curr Top Med Chem; 2009; 9(18):1718-24. PubMed ID: 19929837
[TBL] [Abstract][Full Text] [Related]
37. Fragment-based drug discovery-the importance of high-quality molecule libraries.
Bon M; Bilsland A; Bower J; McAulay K
Mol Oncol; 2022 Nov; 16(21):3761-3777. PubMed ID: 35749608
[TBL] [Abstract][Full Text] [Related]
38. Protein-protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies.
Lucero B; Francisco KR; Liu LJ; Caffrey CR; Ballatore C
Trends Pharmacol Sci; 2023 Jul; 44(7):474-488. PubMed ID: 37263826
[TBL] [Abstract][Full Text] [Related]
39. Ligand and Target Discovery by Fragment-Based Screening in Human Cells.
Parker CG; Galmozzi A; Wang Y; Correia BE; Sasaki K; Joslyn CM; Kim AS; Cavallaro CL; Lawrence RM; Johnson SR; Narvaiza I; Saez E; Cravatt BF
Cell; 2017 Jan; 168(3):527-541.e29. PubMed ID: 28111073
[TBL] [Abstract][Full Text] [Related]
40. Native Mass Spectrometry in Fragment-Based Drug Discovery.
Pedro L; Quinn RJ
Molecules; 2016 Jul; 21(8):. PubMed ID: 27483215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
